Predictive value of plasma proenkephalin and neutrophil gelatinase-associated lipocalin in acute kidney injury and mortality in cardiogenic shock

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/329030

Lähdeviite

CardShock Investigators , Jäntti , T , Tarvasmäki , T , Harjola , V-P , Pulkki , K , Turkia , H , Sabell , T , Tolppanen , H , Jurkko , R , Hongisto , M , Kataja , A , Sionis , A , Silva-Cardoso , J , Banaszewski , M , DiSomma , S , Mebazaa , A , Haapio , M & Lassus , J 2021 , ' Predictive value of plasma proenkephalin and neutrophil gelatinase-associated lipocalin in acute kidney injury and mortality in cardiogenic shock ' , Annals of intensive care , vol. 11 , no. 1 , 25 . https://doi.org/10.1186/s13613-021-00814-8

Julkaisun nimi: Predictive value of plasma proenkephalin and neutrophil gelatinase-associated lipocalin in acute kidney injury and mortality in cardiogenic shock
Tekijä: CardShock Investigators; Jäntti, Toni; Tarvasmäki, Tuukka; Harjola, Veli-Pekka; Pulkki, Kari; Turkia, Heidi; Sabell, Tuija; Tolppanen, Heli; Jurkko, Raija; Hongisto, Mari; Kataja, Anu; Sionis, Alessandro; Silva-Cardoso, Jose; Banaszewski, Marek; DiSomma, Salvatore; Mebazaa, Alexandre; Haapio, Mikko; Lassus, Johan
Tekijän organisaatio: Kardiologian yksikkö
HUS Heart and Lung Center
Helsinki University Hospital Area
University of Helsinki
Clinicum
HUS Emergency Medicine and Services
Department of Medicine
Department of Clinical Chemistry and Hematology
HUSLAB
Department of Diagnostics and Therapeutics
HUS Internal Medicine and Rehabilitation
HUS Abdominal Center
Nefrologian yksikkö
Päiväys: 2021-02-05
Kieli: eng
Sivumäärä: 15
Kuuluu julkaisusarjaan: Annals of intensive care
ISSN: 2110-5820
DOI-tunniste: https://doi.org/10.1186/s13613-021-00814-8
URI: http://hdl.handle.net/10138/329030
Tiivistelmä: Background: Acute kidney injury (AKI) is a frequent form of organ injury in cardiogenic shock. However, data on AKI markers such as plasma proenkephalin (P-PENK) and neutrophil gelatinase-associated lipocalin (P-NGAL) in cardiogenic shock populations are lacking. The objective of this study was to assess the ability of P-PENK and P-NGAL to predict acute kidney injury and mortality in cardiogenic shock. Results: P-PENK and P-NGAL were measured at different time points between baseline and 48 h in 154 patients from the prospective CardShock study. The outcomes assessed were AKI defined by an increase in creatinine within 48 h and all-cause 90-day mortality. Mean age was 66 years and 26% were women. Baseline levels of P-PENK and P-NGAL (median [interquartile range]) were 99 (71-150) pmol/mL and 138 (84-214) ng/mL. P-PENK > 84.8 pmol/mL and P-NGAL > 104 ng/mL at baseline were identified as optimal cut-offs for AKI prediction and independently associated with AKI (adjusted HRs 2.2 [95% CI 1.1-4.4, p = 0.03] and 2.8 [95% CI 1.2-6.5, p = 0.01], respectively). P-PENK and P-NGAL levels at baseline were also associated with 90-day mortality. For patients with oliguria <0.5 mL/kg/h for > 6 h before study enrollment, 90-day mortality differed significantly between patients with low and high P-PENK/P-NGAL at baseline (5% vs. 68%, p <0.001). However, the biomarkers provided best discrimination for mortality when measured at 24 h. Identified cut-offs of P-PENK24h > 105.7 pmol/L and P-NGAL(24h) > 151 ng/mL had unadjusted hazard ratios of 5.6 (95% CI 3.1-10.7, p <0.001) and 5.2 (95% CI 2.8-9.8, p <0.001) for 90-day mortality. The association remained significant despite adjustments with AKI and two risk scores for mortality in cardiogenic shock. Conclusions: High levels of P-PENK and P-NGAL at baseline were independently associated with AKI in cardiogenic shock patients. Furthermore, oliguria before study inclusion was associated with worse outcomes only if combined with high baseline levels of P-PENK or P-NGAL. High levels of both P-PENK and P-NGAL at 24 h were found to be strong and independent predictors of 90-day mortality.
Avainsanat: Cardiogenic shock
Acute kidney injury
AKI
Mortality
Prognosis
Proenkephalin
PENK
NGAL
MANAGEMENT
BIOMARKER
STATEMENT
PROGNOSIS
OUTCOMES
3126 Surgery, anesthesiology, intensive care, radiology
3121 General medicine, internal medicine and other clinical medicine
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: cc_by
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: publishedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
s13613_021_00814_8.pdf 1.765MB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot